{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T05:36:48Z","timestamp":1669441008299},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,3,1]]},"DOI":"10.1093\/pm\/pnx091","type":"journal-article","created":{"date-parts":[[2017,5,19]],"date-time":"2017-05-19T14:20:52Z","timestamp":1495203652000},"page":"419-428","source":"Crossref","is-referenced-by-count":6,"title":["Effect of Baseline Characteristics on the Pain Response to Pregabalin in Fibromyalgia Patients with Comorbid Depression"],"prefix":"10.1093","volume":"19","author":[{"given":"Stuart L","family":"Silverman","sequence":"first","affiliation":[{"name":"OMC Clinical Research Center, UCLA School of Medicine, Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miroslav","family":"Backonja","sequence":"additional","affiliation":[{"name":"University of Wisconsin, Madison, Wisconsin"},{"name":"WorldWide Clinical Trials, Morrisville, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne","family":"Pauer","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Groton, Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaren","family":"Landen","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Groton, Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pritha","family":"Bhadra Brown","sequence":"additional","affiliation":[{"name":"Pfizer Inc., New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph M","family":"Scavone","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Groton, Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Vissing","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Louisville, Kentucky, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Clair","sequence":"additional","affiliation":[{"name":"Pfizer Inc., New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,5,19]]},"reference":[{"key":"key\n\t\t\t\t20180316085246_pnx091-B1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/art.1780380104","article-title":"The prevalence and characteristics of fibromyalgia in the general population","volume":"38","author":"Wolfe","year":"1995","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B2","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/acr.21931","article-title":"Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: Results from a survey of the general population","volume":"65","author":"Wolfe","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B3","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.semarthrit.2008.12.003","article-title":"Prevalence of fibromyalgia: A survey in five European countries","volume":"39","author":"Branco","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B4","first-page":"1570","article-title":"The London Fibromyalgia Epidemiology Study: The prevalence of fibromyalgia syndrome in London, Ontario","volume":"26","author":"White","year":"1999","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B5","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/art.1780330203","article-title":"The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee","volume":"33","author":"Wolfe","year":"1990","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B6","doi-asserted-by":"crossref","first-page":"201.","DOI":"10.1186\/ar4441","article-title":"Review of pharmacological therapies in fibromyalgia syndrome","volume":"16","author":"Hauser","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B7","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/ard.2007.071522","article-title":"EULAR evidence-based recommendations for the management of fibromyalgia syndrome","volume":"67","author":"Carville","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40122-013-0011-1","article-title":"Interpreting effect sizes and clinical relevance of pharmacological interventions for fibromyalgia","volume":"2","author":"Arnold","year":"2013","journal-title":"Pain Ther"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2165\/11598970-000000000-00000","article-title":"The role of antidepressants in the management of fibromyalgia syndrome: A systematic review and meta-analysis","volume":"26","author":"Hauser","year":"2012","journal-title":"CNS Drugs"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B10","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/rheumatology\/kep432","article-title":"Pregabalin in fibromyalgia: Meta-analysis of efficacy and safety from company clinical trial reports","volume":"49","author":"Straube","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B11","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/j.1532-2149.2012.00234.x","article-title":"Longitudinal patterns of analgesic and central acting drug use and associated effectiveness in fibromyalgia","volume":"17","author":"Wolfe","year":"2013","journal-title":"Eur J Pain"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B12","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jpain.2008.03.013","article-title":"A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia","volume":"9","author":"Arnold","year":"2008","journal-title":"J Pain"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B13","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.pain.2008.02.027","article-title":"Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): A 6-month, double-blind, placebo-controlled trial with pregabalin","volume":"136","author":"Crofford","year":"2008","journal-title":"Pain"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B14","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/art.20983","article-title":"Pregabalin for the treatment of fibromyalgia syndrome: Results of a randomized, double-blind, placebo-controlled trial","volume":"52","author":"Crofford","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B15","first-page":"502","article-title":"A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia","volume":"35","author":"Mease","year":"2008","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B16","doi-asserted-by":"crossref","first-page":"R217.","DOI":"10.1186\/ar4056","article-title":"A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia","volume":"14","author":"Ohta","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B17","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.3899\/jrheum.110569","article-title":"An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia","volume":"38","author":"Pauer","year":"2011","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B18","author":"Lyrica Prescribing Information","year":"2013"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B19","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1517\/14656566.2010.509717","article-title":"Treatment response to pregabalin in fibromyalgia pain: Effect of patient baseline characteristics","volume":"11","author":"Emir","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B20","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1526-4637.2007.00332.x","article-title":"The effect of anxiety and depression on improvements in pain in a randomized, controlled trial of pregabalin for treatment of fibromyalgia","volume":"8","author":"Arnold","year":"2007","journal-title":"Pain Med"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B21","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0033-3182(10)70741-6","article-title":"Relationships among pain and depressive and anxiety symptoms in clinical trials of pregabalin in fibromyalgia","volume":"51","author":"Arnold","year":"2010","journal-title":"Psychosomatics"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B22","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1517\/14656566.2010.525217","article-title":"Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: Pooled analysis of phase III clinical trials","volume":"11","author":"Bhadra","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B23","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/ijcp.12035","article-title":"Evaluation of the fibromyalgia impact questionnaire at baseline as a predictor for time to pain improvement in two clinical trials of pregabalin","volume":"67","author":"Bushmakin","year":"2013","journal-title":"Int J Clin Pract"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B24","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00296-010-1713-x","article-title":"Individuals with fibromyalgia and depression: Findings from a nationally representative Canadian survey","volume":"32","author":"Fuller-Thomson","year":"2012","journal-title":"Rheumatol Int"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B25","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3899\/jrheum.141196","article-title":"Efficacy and safety of pregabalin in patients with fibromyalgia and comorbid depression taking concurrent antidepressant medication: A randomized, placebo-controlled study","volume":"42","author":"Arnold","year":"2015","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B26","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0304-3959(94)00178-H","article-title":"When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function","volume":"61","author":"Serlin","year":"1995","journal-title":"Pain"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B27","first-page":"728","article-title":"The fibromyalgia impact questionnaire: Development and validation","volume":"18","author":"Burckhardt","year":"1991","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B28","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.3899\/jrheum.081090","article-title":"Minimal clinically important difference in the fibromyalgia impact questionnaire","volume":"36","author":"Bennett","year":"2009","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B29","volume-title":"The Hospital Anxiety and Depression Scale Manual","author":"Snaith","year":"1994"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B30","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders, 5th Edition.","author":"American Psychiatric Association","year":"2013"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B31","doi-asserted-by":"crossref","first-page":"71.","DOI":"10.1186\/1477-7525-9-71","article-title":"The comparative burden of mild, moderate and severe fibromyalgia: Results from a cross-sectional survey in the United States","volume":"9","author":"Schaefer","year":"2011","journal-title":"Health Qual Life Outcomes"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2165\/11535250-000000000-00000","article-title":"Impact of fibromyalgia severity on health economic costs: Results from a European cross-sectional study","volume":"9","author":"Winkelmann","year":"2011","journal-title":"Appl Health Econ Health Policy"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B33","first-page":"415","article-title":"The comparative economic burden of mild, moderate, and severe fibromyalgia: Results from a retrospective chart review and cross-sectional survey of working-age U.S. adults","volume":"18","author":"Chandran","year":"2012","journal-title":"J Manag Care Pharm"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B34","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1111\/j.1742-1241.2010.02418.x","article-title":"Characteristics of patients with fibromyalgia in France and Germany","volume":"64","author":"Perrot","year":"2010","journal-title":"Int J Clin Pract"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B35","doi-asserted-by":"crossref","first-page":"22.","DOI":"10.1186\/1471-2474-13-22","article-title":"Societal and individual burden of illness among fibromyalgia patients in France: Association between disease severity and OMERACT core domains","volume":"13","author":"Perrot","year":"2012","journal-title":"BMC Musculoskelet Disord"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B36","doi-asserted-by":"crossref","first-page":"66.","DOI":"10.1186\/1471-2474-11-66","article-title":"Toward characterization and definition of fibromyalgia severity","volume":"11","author":"Silverman","year":"2010","journal-title":"BMC Musculoskelet Disord"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B37","first-page":"588","article-title":"Chronic widespread musculoskeletal pain with or without fibromyalgia: Psychological distress in a representative community adult sample","volume":"29","author":"White","year":"2002","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B38","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/00006842-199711000-00002","article-title":"Psychosocial factors in fibromyalgia compared with rheumatoid arthritis: I. Psychiatric diagnoses and functional disability","volume":"59","author":"Walker","year":"1997","journal-title":"Psychosom Med"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B39","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jad.2010.07.004","article-title":"Fibromyalgia syndrome and depressive symptoms: Comorbidity and clinical correlates","volume":"128","author":"Aguglia","year":"2011","journal-title":"J Affect Disord"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B40","doi-asserted-by":"crossref","first-page":"127.e1","DOI":"10.1016\/j.ejpain.2009.03.010","article-title":"Depression, anxiety, health-related quality of life and pain in patients with chronic fibromyalgia and neuropathic pain","volume":"14","author":"Gormsen","year":"2010","journal-title":"Eur J Pain"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B41","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00296-008-0551-6","article-title":"A comparative evaluation of health related quality of life and depression in patients with fibromyalgia syndrome and rheumatoid arthritis","volume":"28","author":"Tander","year":"2008","journal-title":"Rheumatol Int"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B42","first-page":"1621","article-title":"Depression and fibromyalgia: Treatment and cost when diagnosed separately or concurrently","volume":"31","author":"Robinson","year":"2004","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B43","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1093\/pm\/pnw098","article-title":"Pregabalin improves pain scores in patients with fibromyalgia irrespective of comorbid osteoarthritis","volume":"17","author":"Argoff","year":"2016","journal-title":"Pain Med"},{"key":"key\n\t\t\t\t20180316085246_pnx091-B44","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/AJP.0000000000000232","article-title":"Prior opioid use does not impact the response to pregabalin in patients with fibromyalgia","volume":"32","author":"Argoff","year":"2016","journal-title":"Clin J Pain"}],"container-title":["Pain Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/painmedicine\/article-pdf\/19\/3\/419\/24374469\/pnx091.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T21:26:28Z","timestamp":1569360388000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/painmedicine\/article\/19\/3\/419\/3835963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,19]]},"references-count":44,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,5,19]]},"published-print":{"date-parts":[[2018,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/pm\/pnx091","relation":{},"ISSN":["1526-2375","1526-4637"],"issn-type":[{"value":"1526-2375","type":"print"},{"value":"1526-4637","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,3]]},"published":{"date-parts":[[2017,5,19]]}}}